ArticleCureus2026
Immune Checkpoint Inhibitor Overlap Syndrome: Myocarditis, Myositis, and Myasthenia Gravis in a Patient With Metastatic Melanoma.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors can produce severe immune-mediated toxicity involving multiple organ systems. A rare manifestation is the myocarditis, myositis, and myasthenia gravis (MMM) overlap syndrome, also referred to as triple M syndrome or immune-related MMM overlap syndrome, characterized by concurrent myocarditis, myositis, and myasthenia gravis and capable of rapid progression to life-threatening cardiac and neuromuscular complications. A 78-year-old man with metastatic melanoma developed palpitations, profound fatigue, proximal muscle weakness, diplopia, and ptosis two weeks after initiation of nivolumab and ipilimumab. Initial evaluation revealed marked elevations in high-sensitivity troponin (11,399 ng/L), creatine kinase (6,046 U/L), and transaminases, with sinus tachycardia on electrocardiography and preserved systolic function on echocardiography. Intravenous methylprednisolone was started, and immunotherapy was discontinued; however, his biomarkers continued to rise, and his condition rapidly deteriorated after transferring to a tertiary cardiac intensive care unit. He developed a complete heart block requiring transvenous pacing and subsequently demonstrated severe biventricular systolic dysfunction on cardiac imaging. Coronary angiography showed no obstructive disease. Despite escalation to pulse-dose steroids, his neuromuscular weakness worsened, and he progressed to respiratory failure requiring mechanical ventilation, followed by malignant ventricular arrhythmias and hemodynamic collapse before additional therapies, including plasmapheresis, could be initiated. Care was transitioned to comfort measures, and death occurred shortly thereafter. Endomyocardial biopsy confirmed lymphocytic myocarditis with myocyte necrosis. This case highlights that early neuromuscular symptoms accompanied by marked troponin and creatine kinase elevation may represent the first manifestations of MMM overlap syndrome and can precede rapid progression to life-threatening cardiac and respiratory complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.